GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Diurnal Group launches placing and open offer to fund drug development

Tue, 28th May 2019 13:32

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.The AIM-traded firm said it had conditionally raised around £5.35m before expenses by the placing of 20,576,924 placing shares, at a price of 26p each.It said it was also making an open offer, for up to 3,857,617 million new ordinary shares, to raise up to approximately £1m, on the basis of one open offer share for every 16 existing ordinary shares held by qualifying shareholders at the record date.The open offer would provide qualifying shareholders with the opportunity to subscribe for new ordinary shares up until 13 June.It said the net proceeds of the placing and open offer would be used to progress the development and commercialisation of Diurnal's products, including filing a market authorisation application (MAA) for 'Chronocort' in Europe by the end of 2019.They would also be used to file a new drug application (NDA) for 'Alkindi' in the US by the end of 2019, and continuing the development of the European commercial organisation and roll-out of Alkindi in Europe to maximise revenues.Finally, it would be used to progress licensing discussions for Alkindi and Chronocort in the US and the rest of the world.The board said the placing price represented a discount of about 16.1% to the mid-market closing price of its ordinary shares on 24 May, being the last practicable date prior to the date of its announcement.Diurnal said the placing and open offer remained conditional on, amongst other things, the passing of the resolutions to be considered by shareholders at a general meeting on 14 June."Diurnal has continued to make strong progress across its business, including the successful launch of Alkindi in Europe and confirmation of the regulatory paths for Chronocort in Europe and Alkindi in the US, where regulatory submissions are planned for the fourth quarter of 2019," said chief executive officer Martin Whitaker."The funds raised will allow us to progress our vision of becoming a world-leading specialty pharma company in endocrinology, in particular to support the commercial infrastructure for the further roll-out of Alkindi in Europe, paving the way for the expected future launch of Chronocort, and to secure partnerships for Alkindi and Chronocort outside of Europe."
More News
25 Jul 2018 09:39

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.The intellectual property-based to

Read more
18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Read more
3 Apr 2018 16:19

Diurnal To Raise GBP10.5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The

Read more
20 Mar 2018 18:28

Diurnal Nets GBP500,000 From Broker Option Exercise (ALLISS)

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Tuesday said that it has received a letter of notice to exercise the broker option in respect of 263,157 in

Read more
12 Mar 2018 13:51

UPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss

Read more
12 Mar 2018 10:18

Diurnal Interim Loss Widens On Cost Rise As Prepares For First Revenue

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its

Read more
12 Mar 2018 05:17

UK Stocks-Factors to watch on March 12

March 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal

Read more
25 Jan 2017 09:31

Diurnal Agrees Two Deals With UDG Healthcare Ahead Of Infacort Launch

Read more
17 Jan 2017 15:43

DIRECTOR DEALINGS: Diurnal Non-Executive Ups Interest

Read more
16 Jan 2017 15:08

Director dealings: Diurnal trio dip in after EMA submission in December

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri

Read more
12 Jan 2017 09:04

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

Read more
20 Dec 2016 12:23

Diurnal Submits European Marketing Application For Infacort

Read more
21 Nov 2016 09:32

Diurnal Doses First Testosterone Replacement Therapy Trial Patients

Read more
5 Oct 2016 15:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
11 Jul 2016 08:00

Diurnal and IP Group eye 2017 launch for childhood hormonal treatment

(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.